Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Senseonics Holdings ( (SENS) ) has issued an update.
On January 12, 2026, Senseonics reported preliminary unaudited revenue of approximately $14.2 million for the fourth quarter of 2025 and $35.2 million for full-year 2025, representing year-over-year growth of 71% and about 57% respectively and marking the highest quarterly and annual revenue in the company’s history. The company’s cash, cash equivalents and restricted cash were estimated at about $94.3 million as of December 31, 2025, while its U.S. patient base more than doubled in the fourth quarter, up 103% from a year earlier, driven largely by direct-to-consumer marketing; operationally, Senseonics advanced its pipeline with FDA IDE approval and first patient enrollment for the pivotal Gemini sensor trial, initiated commercial use of pump partner Sequel’s twiist insulin delivery system compatible with Eversense 365, and executed agreements for Ascensia Diabetes Care to assume U.S. commercialization and distribution of Eversense starting January 1, 2026, developments that collectively strengthen its competitive position in the CGM market.
The most recent analyst rating on (SENS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.
Spark’s Take on SENS Stock
According to Spark, TipRanks’ AI Analyst, SENS is a Neutral.
The score is weighed down primarily by weak financial performance (ongoing losses and high leverage) and bearish technicals (price below major moving averages with negative MACD). Positive earnings-call momentum and strategic commercialization changes provide upside potential but do not yet offset the profitability and balance-sheet risks.
To see Spark’s full report on SENS stock, click here.
More about Senseonics Holdings
Senseonics Holdings, Inc. is a medical technology company that develops and manufactures long-term, implantable continuous glucose monitoring systems for adults with diabetes. Its flagship products, the Eversense 365 and Eversense E3 CGM systems, use a small subcutaneous sensor that communicates with a smart transmitter and mobile app, targeting the global diabetes community with differentiated year-long and six-month glucose monitoring solutions.
Average Trading Volume: 477,067
Technical Sentiment Signal: Strong Sell
Current Market Cap: $290.9M
See more data about SENS stock on TipRanks’ Stock Analysis page.